The first designs have been released of the housing-led redevelopment of GlaxoSmithKline’s former west London HQ, drawn up by ...

The report, released last month, was backed by the government and sponsored by Lloyds Banking Group and KPMG. Ahead of ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experie ...

who has led UK Biobank since it was set up in 2002. The study will kick off by testing 300,000 samples – 250,000 first and 50,000 second samples - at the Regeneron Genetics Center in the US ...

LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...

CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that GSK plc (LON:GSK) is about to go ex-dividend in just ...

Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...